AI assistant
HAEMONETICS CORP — Director's Dealing 2020
May 19, 2020
31565_dirs_2020-05-19_04cbd167-a503-4b52-9dfb-d2faa1b2f2f8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2020-05-18
Reporting Person: Lingamneni Anila (EVP, Chief Technology Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-05-18 | Common Stock | A | 1209 | — | Acquired | 3390 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-05-18 | Non-qualified Stock Option (Right to Buy) | $103.37 | A | 4092 | Acquired | 2027-05-18 | Common Stock (4092) | Direct |
Footnotes
F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.
F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
F3: This number includes unvested RSUs previously reported.
F4: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.